Teva Pharmaceutical Industries Limited (TEVA) Return on Equity ROE from the third quarter 2026 to third quarter 2025 and annually, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Teva Pharmaceutical Industries Limited  (NYSE: TEVA)

Teva Pharmaceutical Industries Limited's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Teva Pharmaceutical Industries Limited in the third quarter 2026?
Teva Pharmaceutical Industries Limited achieved a return on average equity (ROE) of 6.37 % in its third quarter 2026, this is above TEVA's average return on equity of -5.17%.
Teva Pharmaceutical Industries Limiteds equity during the 12 months ending in the third quarter 2026 are valued at $7 billion

ROE fell compared to the second quarter 2026, despite the net income growth of % from the second quarter 2026.

Within the Major Pharmaceutical Preparations industry 54 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 637, from total ROE ranking in the second quarter 2026 at 732.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Equity Change 10.12 % 13.51 % 31.25 % 47.03 % -
Y / Y Net Income Change -46.31 % - 67.73 % - -
Net Income (TTM) in Millions 508 709 1,567 1,418 661
Return On Equity (TTM) 6.37 % 9.11 % 20.74 % 20.07 % 10.27 %
TEVA's Total Ranking # 637 # 732 # 1353 # 2505 # 3026
Equity (TTM) in Millions 7,984 7,757 8,228 7,910 7,250
Seq. Equity Change 2.93 % -5.72 % 4.02 % 9.1 % 6.09 %
Seq. Net Income Change - - -23.28 % 10.83 % 53.36 %

Back to TEVA Management Effectiveness >> TEVA's 5 Years Annual ROE >> Compare TEVA ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 55
Sector # 160
Overall # 637

Return On Equity Statistics
High Average Low
20.74 %
-5.17 %
-66.82 %
(Mar 31 2026)   (Mar 31 2018)





TEVA Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 7,910 5,380 8,126 8,598 11,244
Y / Y Equity Change 47.03 % -33.79 % -5.49 % -23.53 % 1.65 %
Net Income in Millions 1,418 -1,959 -615 -2,499 456
Y / Y Net Income Change - - - - -
Return On Equity 17.93 % -36.41 % -7.57 % -29.06 % 4.06 %

Back to TEVA Management Effectiveness >> TEVA's 5 Years Annual ROE >> Compare TEVA ROE to its Competitors




Annual Roe Comment
In 2025 ROE improved to 17.93 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
TEVA's' Return on Equity at Yahoo Finance
TEVA's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for TEVA's Competitors
Subscribers only: Roe for Teva Pharmaceutical Industries Limited's Suppliers
Subscribers only: Return On Equity for TEVA's Customers




Companies with similar Return On Equity at Sep 30 2026, within Healthcare Sector ROE
Pediatrix Medical Group Inc   17.28 %
Kiniksa Pharmaceuticals International Plc  17.27 %
Krystal Biotech Inc   17.02 %
Intuitive Surgical Inc   16.99 %
Ensign Group Inc  16.62 %
Lemaitre Vascular Inc   15.81 %
Stryker Corp  15.61 %
Quest Diagnostics Inc  15.22 %
Regeneron Pharmaceuticals Inc   15.07 %
Bio rad Laboratories Inc   14.07 %
Boston Scientific Corporation  13.75 %
Inspire Medical Systems inc   12.49 %
Haemonetics Corporation  12.07 %
Labcorp Holdings Inc   11.55 %
Henry Schein Inc   11.29 %
Medinotec Inc   10.97 %
Tactile Systems Technology Inc   10.73 %
Penumbra Inc  10.44 %
Teleflex Incorporated  9.67 %
Merit Medical Systems Inc  9.65 %
U S Physical Therapy Inc  9.48 %
Pacific Health Care Organization Inc  8.10 %
Incyte Corporation  7.08 %
Conmed Corporation  7.07 %
Teva Pharmaceutical Industries Limited  6.37 %
Integer Holdings Corporation  6.02 %
Avantor Inc   5.96 %
Ligand Pharmaceuticals Incorporated  5.22 %
Lifestance Health Group Inc   4.82 %
Jazz Pharmaceuticals Plc  4.62 %

Date modified: 2026-11-05T14:30:35+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.